EP4 Receptor Antagonist Synthesis via D-Proline Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EP4 receptor antagonists, such as CR6086, have complex synthetic routes that make them costly and time-consuming to produce, necessitating the development of simpler and more cost-effective alternatives for treating diseases associated with prostaglandin E2 (PGE2) activity.
Innovation Solution
The development of (R)-4-(1-(1-(4-(trifluoromethyl)benzyl) pyrrolidin-2-carboxamide) cyclopropyl benzoic acid (Compound 1) and its pharmaceutically acceptable salts, which are potent and selective antagonists of the EP4 receptor, using simplified synthesis processes involving D-proline and reduced step procedures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CR6086 is synthesized using the conventional 8-step route, then high affinity and selectivity for EP4 receptor is achieved, but the synthesis complexity and production cost increase significantly
Solution Approach 1:
The synthesis is divided into modular stages: (a) amide bond formation between N-Boc-D-proline and methyl 4-(1-aminocyclopropyl) benzoate, (b) Boc group deprotection to reveal the amine, (c) alkylation with 4-trifluoromethyl benzyl bromide, and (d) ester hydrolysis. Each stage uses standardized reagents and conditions, reducing overall complexity while maintaining product quality.
Solution Approach 2:
The invention changes the starting material from complex spirocyclic structures to simple D-proline, and modifies reaction conditions to use commercially available reagents under mild conditions. This parameter change simplifies the synthesis pathway while preserving the critical pharmacophore features for EP4 receptor binding.
2Reliability
If CR6086 is synthesized using the conventional 8-step route, then high affinity and selectivity for EP4 receptor is achieved, but production time and cost increase
Solution Approach 1:
The synthesis plan is designed in advance with clearly defined intermediate structures and protected group strategies. The Boc protection group is strategically used to enable sequential reactions without side reactions, and each intermediate is designed to be easily purified. This preliminary planning reduces actual execution time and improves production efficiency.
Solution Approach 2:
The synthesis pathway is designed to minimize idle time between reactions. Each step flows logically into the next, with intermediates that can be carried forward without extensive purification. The continuous transformation from simple starting materials to the final product maintains productive momentum throughout the synthesis sequence.
3Productivity
If simpler synthesis routes are used for EP4 antagonists, then production cost and time are reduced, but the ability to effectively inhibit PGE2-mediated activities may be compromised
Solution Approach 1:
The invention uses inexpensive, commercially available starting materials like D-proline and standard reagents (EDC, HOBt, TFA) that can be readily obtained. These simple, disposable materials are transformed through efficient reactions to create the complex pharmacologically active compound, achieving cost reduction without sacrificing efficacy.
Solution Approach 2:
The critical pharmacophore elements (pyrrolidine ring, carboxamide group, cyclopropyl benzoic acid moiety, and trifluoromethyl substitution) are preserved through careful reaction condition selection. The simplification occurs in the synthesis pathway, not in the molecular structure, ensuring PGE2 inhibition efficacy is maintained while production becomes more efficient.
Data Source
AI summary
The following invention relates to (R)-4-(1-(1-(4-(trifluoromethyl)benzyl) pyrrodiline-2-carboxamide) cyclopropyl benzoic acid (Compound 1) or a salt thereof. Advantageous methods for obtaining the Compound 1 are also described, as well as pharmaceutical compositions containing it (R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrodiline-2-carboxamide) cyclopropyl benzoic acid (Compound 1) or a pharmaceutically acceptable salt thereof is described for use as an EP4 receptor antagonist in the treatment of a pathology that involves the activities of prostaglandin E2 (PGE2) in its pathogenesis.